Biochemical and immunological studies on erythrocytes superoxide dismutase modified by nitric oxide in patients with alopecia areata: Implications in alopecia patchy persistent and alopecia universalis

Immunology Letters

Volumn 160, Issue 1, 2014, Pages 50-57

  Rasheed, Zafar ^a   Alzolibani, Abdullateef A ^a   Al Shobaili, Hani A ^a   Saif, Ghada Bin ^b   Al Robaee, Ahmad A ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

AA autoimmunity; Alopecia areata; Alopecia patchy persistent; Alopecia universalis; Erythrocytes superoxide dismutase; Nitric oxide; NO eSOD

Indexed keywords

AROMATIC AMINO ACID; CARBONYL DERIVATIVE; ERYTHROCYTE SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN G; NITRIC OXIDE; PROTEIN A; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ALOPECIA AREATA; ALOPECIA AREATA PERSISTENT; ALOPECIA TOTALIS; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; YOUNG ADULT; DRUG EFFECTS; ENZYME ACTIVATION; ERYTHROCYTE; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION;

ADULT; ALOPECIA; ALOPECIA AREATA; ENZYME ACTIVATION; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATION-REDUCTION; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84899692753     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.03.007     Document Type: Article

References (40)

1. Madani S., Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000, 42:549-566.
2. Rosenstein E.D., Warshauer B.L. Alopecia areata and autoimmunity. J Am Acad Dermatol 2010, 62:1065.
3. Bertolini M., Gilhar A., Paus R. Alopecia areata as a model for T cell-dependent autoimmune diseases. Exp Dermatol 2012, 21:477-479.
4. Gilhar A., Etzioni A., Paus R. Alopecia areata. N Engl J Med 2012, 366:1515-1525.
5. Barahmani N., Schabath M.B., Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009, 61(October (4)):581-591.
6. Hordinsky M., Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 2004, 9:73-78.
7. Kim S.W., Kim B.J., Youn S.W., Park K.C., Huh C.H. Evaluation of free oxygen radical and antioxidant capacity in alopecia areata. Dermatology 2010, 37:762-764.
8. Abdel Fattah N.S., Ebrahim A.A., El Okda E.S. Lipid peroxidation/antioxidant activity in patients with alopecia areata. J Eur Acad Dermatol Venereol 2011, 25:403-408.
9. Akar A., Arca E., Erbil H., Akay C., Sayal A., Gur A.R. Antioxidant enzymes and lipid peroxidation in the scalp of patients with alopecia areata. J Dermatol Sci 2002, 29:85-90.
10. Shah A.A., Sinha A.A. Oxidative stress and autoimmune disease. Eur J Dermatol 2013, 23:5-13.
11. Al-Shobaili H.A., Alzolibani A.A., Al Robaee A.A., Meki A.R., Rasheed Z. Biochemical markers of oxidative and nitrosative stress in acne vulgaris: correlation with disease activity. J Clin Lab Anal 2013, 27:45-52.
12. Laddha N.C., Dwivedi M., Mansuri M.S., Gani A.R., Ansarullah M., Ramachandran A.V., et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 2013, 22:245-250.
13. Bakry O.A., Elshazly R.M., Shoeib M.A., Gooda A. Oxidative stress in alopecia areata: a case-control study. Am J Clin Dermatol 2014, 15:57-64.
14. Namazi M.R. Nitric oxide donors as potential additions to anti-alopecia areata armamentarium. Inflamm Res 2003, 52:227-229.
15. Koca R., Armutcu F., Altinyazar C., Gurel A. Evaluation of lipid peroxidation, oxidant/antioxidant status, and serum nitric oxide levels in alopecia areata. Med Sci Monit 2005, 11:CR296-CR299.
16. Al-Shobaili H.A., Al Robaee A.A., Alzolibani A.A., Rasheed Z. Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: role of chromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE. Dis Markers 2012, 33:19-34.
17. Wang G., Pierangeli S.S., Papalardo E., Ansari G.A., Khan M.F. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
18. Rasheed Z., Ahmad R., Rasheed N., Ali R. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies. Autoimmunity 2007, 40:512-520.
19. Peixoto E.B., Pessoa B.S., Biswas S.K., Lopes de Faria J.B. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension. Am J Nephrol 2009, 29:309-331.
20. Al-Shobaili H.A., Rasheed Z. Immunological studies of oxidized superoxide dismutase in patients with systemic lupus erythematosus: correlation with disease induction and progression. Saudi Med J 2012, 33:1177-1184.
21. Olsen E., Hordinsky M., McDonald-Hull S., Price V., Roberts J., Shapiro J., et al. Alopecia areata investigational assessment guidelines. National alopecia areata foundation. J Am Acad Dermatol 1999, 40:242-246.
22. Dixit K., Ali R. Role of nitric oxide modified DNA in the etiopathogenesis of systemic lupus erythematosus. Lupus 2004, 13:95-100.
23. Al-Shobaili H.A., Al Robaee A.A., Alzolibani A.A., Rasheed Z. Immunological studies of reactive oxygen species damaged catalase in patients with systemic lupus erythematosus: correlation with disease activity index. Immunol Invest 2013, 42:191-203.
24. Rasheed Z., Ali R. Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci 2006, 79:2320-2328.
25. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
26. Rasheed Z. Hydroxyl radical damaged immunoglobulin G in patients with rheumatoid arthritis: biochemical and immunological studies. Clin Biochem 2008, 41:663-669.
27. Rasheed Z., Al-Shobaili H.A., Alzolibani A.A., Ismail Khan M., Ayub T., Khan M.I., et al. Immunological functions of oxidized human immunoglobulin G in type 1 diabetes mellitus: its potential role in diabetic smokers as a biomarker of elevated oxidative stress. Dis Markers 2011, 31:47-54.
28. Alzolibani A.A., Al Robaee A.A., Al-Shobaili H.A., Rasheed Z. 4-hydroxy-2-nonenal modified histone-H2A: a possible antigenic stimulus for systemic lupus erythematosus autoantibodies. Cell Immunol 2013, 284:154-162.
29. Singh R., Ahmed S., Islam N., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate inhibits interleukin-1 beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002, 46:2079-2086.
30. Stryer L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescence probe of non-polar binding sites. J Mol Biol 1965, 13:482-495.
31. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003, 329:23-38.
32. Sulkowska A. Interaction of drugs with bovine and human serum albumin. J Mol Struct 2002, 614:227-232.
33. Rasheed Z., Khan M.W., Ali R. Hydroxyl radical modification of human serum albumin generated cross reactive antibodies. Autoimmunity 2006, 39:479-488.
34. Naziroglu M., Kokcam I. Antioxidants and lipid peroxidation status in the blood of patients with alopecia. Cell Biochem Funct 2000, 18:169-173.
35. Hohn A., Jung T., Grune T. Pathophysiological importance of aggregated damaged proteins. Free Radic Biol Med 2014, March. (in press), pii: S0891-5849(14)00105-1.
36. Chiu-Braga Y.Y., Hayashi S.Y., Schafranski M., Messias-Reason I.J. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006, 109:275-276.
37. Brito C., Naviliat M., Tiscornia A.C., Vuillier F., Gualco G., Dighiero G., et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 1999, 162:3356-3366.
38. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A 1992, 89:3030-3034.
39. Shu L., Vivekanandan-Giri A., Pennathur S., Smid B.E., Aerts J.M., Hollak C.E., et al. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int 2014, January. (in press). 10.1038/ki.2013.520.
40. Batinic-Haberle I., Reboucas J.S., Spasojevic I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 2010, 13:877-918.